Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis

Lago, Eduardo Henrique Jorge; Carneiro, Sueli Coelho da Silva; Cuzzi, Tullia; Magalhães, Geraldo Magela; Cassia, F F; Pessanha, Fátima; Ramos‐e‐Silva, Márcia

doi:10.1111/j.1600-0560.2006.00571.x

Cited by 11 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We consider that our findings are not in conflict with previous reports because CyA can bring about an improvement only on the psoriatic lesions but not affect uninvolved skin. Lago et al (2007) have reported that CyA affects dermal dendrocytes and keratinocytes in psoriatic lesions, but that its main action is on T lymphocytes.…”

Section: Discussionmentioning

confidence: 97%

“…Although the effects of CyA on keratinocytes are well documented, little is known about the effects on dermal fibroblasts (Priqnano et al 1996;Lago et al 2007). Recently, CyA has been reported to modify the synthesis and degradation of extracellular matrix (ECM) by osteoblasts and gingival fibroblasts (Boltchi et al 1999;Fu et al 1999;Fornoni et al 2001;Bostorm et al 2005;Bullon et al 2007).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interleukin-6 counteracts effects of cyclosporin A on extracellular matrix metabolism by human dermal fibroblasts

et al. 2008

View full text Add to dashboard Cite

Although the actions of cyclosporin (CyA) on keratinocyte are well established, little is known about its effects on dermal fibroblasts. Interleukin-6 (IL-6) is one of the inflammatory cytokines playing a pivotal role in certain skin diseases such as psoriasis. The aim of this study has been to determine whether CyA modifies the metabolism of extracellular matrix (ECM) by human fibroblasts in vitro. CyA altered the morphology of fibroblasts in the collagen matrix. Fibroblast proliferation was suppressed by CyA at 100 and 10 ng/ml. The production of type I collagen and tissue inhibitor of metalloproteinase 1 was also suppressed by CyA at 1000 ng/ml, and co-stimulation with IL-6 enhanced decreased production at 1000 and 100 ng/ml CyA. The production of matrix metalloproteinase 1 (MMP-1) was also suppressed by CyA in a dose-dependent manner. In contrast, the decreased production of MMP-1 was restored at 0.1-100 ng/ml CyA in the presence of IL-6. Regardless of the presence or absence of IL-6, the production of MMP-2 decreased at 1000 and 100 ng/ml, whereas the production of MMP-9 was unchanged. The production of transforming growth factor-beta decreased at 100 ng/ml CyA. This study thus indicates that CyA influences ECM metabolism and the proliferation of human dermal fibroblasts, and that the effects of CyA are modulated by IL-6. CyA might also, in part, improve psoriatic skin by regulating the remodeling of ECM and by its action on immunocompetent cells.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Interleukin-6 counteracts effects of cyclosporin A on extracellular matrix metabolism by human dermal fibroblasts

et al. 2008

View full text Add to dashboard Cite

show abstract

“…This suggests that combination therapy led to quicker improvements and more extensive efficacy than etanercept monotherapy alone. Lago et al 4 evaluated 30 patients with psoriasis treated with cyclosporine monotherapy for 8 weeks. Mean PASI before treatment was 26.32, and reduced to 3.71 after treatment.…”

Section: Discussionmentioning

confidence: 99%

A Clinical Trial of Combination Therapy with Etanercept and Low Dose Cyclosporine for the Treatment of Refractory Psoriasis

2010

View full text Add to dashboard Cite

Background: Over the past decade, combination therapies have become a mainstay of dermatologic care in psoriasis. Combination therapies are often more effective and safer than large dose single-agent therapies. With the emergence of new biologic therapies, dermatologists now have a wider array of tools to treat psoriasis. Although much data exists regarding cyclosporine or biologic agents alone for psoriasis, little is known about the efficacy, safety and tolerability of combination regimens. Objective: We designed a study to evaluate the efficacy and safety of etanercept and cyclosporin combination therapy in patients with refractory psoriasis. Methods: We administered oral cyclosporine (200 mg daily) and subcutaneous etanercept 50 mg weekly injections until symptoms improved, then maintained treatment at a reduced dose. Seven patients with refractory psoriasis were evaluated 4 weekly. Results: All 7 patients showed rapid responses to combination therapy. Mean Psoriasis Area and Severity Index reductions following conditioning therapy (mean: 6.85 weeks) and maintenance therapy (mean: 56.5 weeks) were 94.9% and 93.2%, respectively. Conclusion: Etanercept and low-dose cyclosporine combination therapy appears to be a safe and efficacious alternative treatment strategy for patients with refractory psoriasis. The combination induced rapid improvement in patients with refractory psoriasis and dramatically improved their quality of life. Clinical studies including larger patient cohort are required to validate the safety and efficacy of this combination therapy. (Ann Dermatol 22(2) 138∼142, 2010)

show abstract

“…Twenty‐eight studies met the criteria for inclusion in the guidelines. Two grade A 2 studies on cyclosporine mono‐ therapy were included [237, 250], 14 grade B studies [243–245, 247, 251–260], and seven grade C studies [249, 261–266]. The resulting evidence level was 1.…”

Section: Systemic Therapymentioning

confidence: 99%

S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

Nast

Boehncke

Mrowietz

et al. 2012

J Deutsche Derma Gesell

249

247

View full text Add to dashboard Cite

Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5% to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, surveys have shown that patients still do not received optimal treatments. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologi sche Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. They were first published in 2006 and updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate and severe plaque-type psoriasis in adults including systemic therapy, UV therapy and topical therapies. The therapeutic recommendations were developed based on the results of a systematic literature search and were finalized during a consensus meeting using structured consensus methods (nominal group process).

show abstract

Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis

Cited by 11 publications

References 33 publications

Interleukin-6 counteracts effects of cyclosporin A on extracellular matrix metabolism by human dermal fibroblasts

Interleukin-6 counteracts effects of cyclosporin A on extracellular matrix metabolism by human dermal fibroblasts

A Clinical Trial of Combination Therapy with Etanercept and Low Dose Cyclosporine for the Treatment of Refractory Psoriasis

S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

Contact Info

Product

Resources

About